PAR 1.92% 25.5¢ paradigm biopharmaceuticals limited..

Yes, but if a partner wants more data, we should produce it in a...

  1. 286 Posts.
    lightbulb Created with Sketch. 79
    Yes, but if a partner wants more data, we should produce it in a phase 3 trial and why not have a subset of subjects generate this…. now. I’m really happy to see these outcome measurements maintained, even if we are a durable pain and function drug in 2025.

    I understand the costs to monitor/apply for DMOAD and the monitoring required would be financially onerous (unless a partner is sitting and waiting to strike once 2mg dose is approved, trial design is re-worked and adrenal misnomer is addressed.) F@CK knows. As KP said, no one knows (except a few that think they do).

    It’s a piece of information I’ve been waiting for. This is a big moment.

    I wonder if DMOAD label can be attained in Aussie TGA provisional approval?

    I also wonder if a subset of phase 3 stage 2 trial subjects are outcome measured for DMOAD, whether that data can be used for accelerated approval, too.

    Donna, no doubt working on all this. She is a gun. What would we do without her?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
25.5¢
Change
-0.005(1.92%)
Mkt cap ! $89.19M
Open High Low Value Volume
27.0¢ 27.0¢ 25.5¢ $261.4K 990.7K

Buyers (Bids)

No. Vol. Price($)
1 9999 25.5¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 9445 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.